UB Paderborn / Katalog / Suche / in CDI

Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies

Bone marrow transplantation (Basingstoke), 2013-10, Vol.48 (10), p.1279-1284

2013

Volltextzugriff (PDF)

High Rates of Non-Relapse Mortality and Graft-Versus-Host Disease in Patient Undergoing Allogeneic Stem Cell Transplantation (ASCT) Following Non-Myeloablative (NMA) Conditioning With TLI/ATG

Biology of blood and marrow transplantation, 2011, Vol.17 (2), p.S313-S313

2011

Volltextzugriff (PDF)

Higher Busulfan Dose Intensity Does Not Improve Outcomes of Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (AHCT) Following Fludarabine/Busulfan/Atg (FBA)-Based Reduced Toxicity Conditioning (RTC)

Biology of blood and marrow transplantation, 2011, Vol.17 (2), p.S306-S306

2011

Volltextzugriff (PDF)

Cyclophosphamide (CY)/G-CSF Cannot Completely Overcome Imid-Induced Impairment of Peripheral Blood Stem Cell (PBSC) Mobilization (Mob) in Patients With Multiple Myeloma (MM)

Biology of blood and marrow transplantation, 2011, Vol.17 (2), p.S204-S204

2011

Volltextzugriff (PDF)

Evaluation Of Busulfan's Dose-Intensity In Patients Undergoing Allogeneic Stem Cell Transplantation (ASCT) With Two Different Fludarabine/Busulfan/ATG (FBA)-Based Reduced Intensity Conditioning (RIC) Regimens

Biology of blood and marrow transplantation, 2010, Vol.16 (2), p.S280-S280

2010

Volltextzugriff (PDF)

Several Metarhizium Species Produce Ergot Alkaloids in a Condition-Specific Manner

Applied and environmental microbiology, 2020-07, Vol.86 (14)

2020

Volltextzugriff (PDF)

Biodiversity of Convolvulaceous species that contain ergot alkaloids, indole diterpene alkaloids, and swainsonine

Biochemical systematics and ecology, 2019-10, Vol.86, p.103921, Article 103921

2019

Volltextzugriff (PDF)

Inequitable Conduct and Invalidation of Patents Related to Food and Drug Administration-Regulated Products

JAMA : the journal of the American Medical Association, 2023-12, Vol.330 (21), p.2119

2023

Volltextzugriff (PDF)

Hematopoietic progenitor cell mobilization with “just-in-time” plerixafor approach is a cost-effective alternative to routine plerixafor use

Cytotherapy (Oxford, England), 2015-12, Vol.17 (12), p.1785-1792

2015

Volltextzugriff (PDF)

Metformin use and allogeneic stem cell transplant (ASCT) outcomes

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e18001-e18001

2014

Volltextzugriff (PDF)

Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF

Journal of clinical apheresis, 2013-10, Vol.28 (5), p.359-367

2013

Volltextzugriff (PDF)

Cost and Efficacy of Upfront Plerixafor Versus a “Just-in-Time” (JIT) Approach in Hematopoietic Progenitor Cell (HPC) Mobilization

Blood, 2014-12, Vol.124 (21), p.1127-1127

2014

Volltextzugriff (PDF)

Impact of body mass index (BMI) on plerixafor efficacy during hematopoietic progenitor cell (HPC) mobilization

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.7047-7047

2014

Volltextzugriff (PDF)

Predictors and Impact Of 30-Day Readmissions On Patient Outcomes and Healthcare Costs After Allogeneic Hematopoietic Cell Transplantation

Blood, 2013-11, Vol.122 (21), p.1718-1718

2013

Volltextzugriff (PDF)

Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies – A Multicenter Analysis

Blood, 2012-11, Vol.120 (21), p.4409-4409

2012

Volltextzugriff (PDF)

Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin

Bone Marrow Research, 2013-01, Vol.2013, p.414959-8

2013

Volltextzugriff (PDF)

Effect of T-Cell Dose On Outcomes After Peripheral Blood Allogeneic Hematopoietic Cell Transplantation in Hematological Malignancies

Blood, 2009-11, Vol.114 (22), p.1171-1171

2009

Volltextzugriff (PDF)

Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies – A Multicenter Analysis

Blood, 2011-11, Vol.118 (21), p.313-313

2011

Volltextzugriff (PDF)

In Vivo T-Cell Depletion Does Not Improve Rates of Graft-Versus-Host Disease and Transplantation Outcomes In Patients Undergoing Peripheral Blood Hematopoietic Cell Transplant

Blood, 2010-11, Vol.116 (21), p.4536-4536

2010

Volltextzugriff (PDF)

Response to Induction Chemotherapy with Novel Agents Does Not Predict Outcomes of Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Blood, 2010-11, Vol.116 (21), p.1347-1347

2010

Volltextzugriff (PDF)

Higher Infused CD34+ Cell Dose Improves Survival In Patients Undergoing In Vivo T-Cell Depleted, but Not T-Cell Replete Peripheral Blood Hematopoietic Cell Transplant

Blood, 2010-11, Vol.116 (21), p.1272-1272

2010

Volltextzugriff (PDF)

Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning

Hematological oncology, 2011-12, Vol.29 (4), p.202-210

2011

Volltextzugriff (PDF)

Predictors and Impact of Thirty-Day Readmission on Patient Outcomes and Health Care Costs after Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation

Biology of blood and marrow transplantation, 2014-03, Vol.20 (3), p.415-420

2014

Volltextzugriff (PDF)

Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Therapies

Biology of blood and marrow transplantation, 2012-07, Vol.18 (7), p.1128-1135

2012

Volltextzugriff (PDF)

Higher infused CD34 + cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation

Hematology/oncology and stem cell therapy, 2011, Vol.4 (4), p.149-156

2011

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies

High Rates of Non-Relapse Mortality and Graft-Versus-Host Disease in Patient Undergoing Allogeneic Stem Cell Transplantation (ASCT) Following Non-Myeloablative (NMA) Conditioning With TLI/ATG

Higher Busulfan Dose Intensity Does Not Improve Outcomes of Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (AHCT) Following Fludarabine/Busulfan/Atg (FBA)-Based Reduced Toxicity Conditioning (RTC)

Cyclophosphamide (CY)/G-CSF Cannot Completely Overcome Imid-Induced Impairment of Peripheral Blood Stem Cell (PBSC) Mobilization (Mob) in Patients With Multiple Myeloma (MM)

Evaluation Of Busulfan's Dose-Intensity In Patients Undergoing Allogeneic Stem Cell Transplantation (ASCT) With Two Different Fludarabine/Busulfan/ATG (FBA)-Based Reduced Intensity Conditioning (RIC) Regimens

Several Metarhizium Species Produce Ergot Alkaloids in a Condition-Specific Manner

Biodiversity of Convolvulaceous species that contain ergot alkaloids, indole diterpene alkaloids, and swainsonine

Inequitable Conduct and Invalidation of Patents Related to Food and Drug Administration-Regulated Products

Hematopoietic progenitor cell mobilization with “just-in-time” plerixafor approach is a cost-effective alternative to routine plerixafor use

Metformin use and allogeneic stem cell transplant (ASCT) outcomes

Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF

Cost and Efficacy of Upfront Plerixafor Versus a “Just-in-Time” (JIT) Approach in Hematopoietic Progenitor Cell (HPC) Mobilization

Impact of body mass index (BMI) on plerixafor efficacy during hematopoietic progenitor cell (HPC) mobilization

Predictors and Impact Of 30-Day Readmissions On Patient Outcomes and Healthcare Costs After Allogeneic Hematopoietic Cell Transplantation

Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies – A Multicenter Analysis

Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin

Effect of T-Cell Dose On Outcomes After Peripheral Blood Allogeneic Hematopoietic Cell Transplantation in Hematological Malignancies

Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies – A Multicenter Analysis

In Vivo T-Cell Depletion Does Not Improve Rates of Graft-Versus-Host Disease and Transplantation Outcomes In Patients Undergoing Peripheral Blood Hematopoietic Cell Transplant

Response to Induction Chemotherapy with Novel Agents Does Not Predict Outcomes of Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Higher Infused CD34+ Cell Dose Improves Survival In Patients Undergoing In Vivo T-Cell Depleted, but Not T-Cell Replete Peripheral Blood Hematopoietic Cell Transplant

Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning

Predictors and Impact of Thirty-Day Readmission on Patient Outcomes and Health Care Costs after Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation

Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Therapies

Higher infused CD34 + cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation

Suchergebnisse filtern